基于造血干细胞的基因治疗艾滋病。
Hematopoietic-stem-cell-based gene therapy for HIV disease.
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
出版信息
Cell Stem Cell. 2012 Feb 3;10(2):137-47. doi: 10.1016/j.stem.2011.12.015.
Abstract
Although combination antiretroviral therapy can dramatically reduce the circulating viral load in those infected with HIV, replication-competent virus persists. To eliminate the need for indefinite treatment, there is growing interest in creating a functional HIV-resistant immune system through the use of gene-modified hematopoietic stem cells (HSCs). Proof of concept for this approach has been provided in the instance of an HIV-infected adult transplanted with allogeneic stem cells from a donor lacking the HIV coreceptor, CCR5. Here, we review this and other strategies for HSC-based gene therapy for HIV disease.
摘要
虽然联合抗逆转录病毒疗法可以显著降低感染 HIV 的人的循环病毒载量，但复制型病毒仍然存在。为了消除对无限期治疗的需求，人们越来越有兴趣通过使用基因修饰的造血干细胞（HSCs）来创建功能性抗 HIV 免疫系统。在接受来自缺乏 HIV 核心受体 CCR5 的供体的同种异体干细胞移植的 HIV 感染成人的情况下，已经为这种方法提供了概念验证。在这里，我们回顾了基于 HSC 的 HIV 疾病基因治疗的这种方法和其他策略。
相似文献
1
Hematopoietic-stem-cell-based gene therapy for HIV disease.基于造血干细胞的基因治疗艾滋病。
Cell Stem Cell. 2012 Feb 3;10(2):137-47. doi: 10.1016/j.stem.2011.12.015.
2
Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease.基于共受体的造血干细胞基因治疗艾滋病。
Curr Stem Cell Res Ther. 2019;14(7):591-597. doi: 10.2174/1574888X14666190523094556.
3
CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.针对 HIV 疾病的 CCR5 靶向造血干细胞基因治疗方法：当前进展和未来展望。
Curr Stem Cell Res Ther. 2012 Jul;7(4):310-7. doi: 10.2174/157488812800793108.
4
Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure.伦敦与柏林的经验：探寻功能性 HIV 治愈方法。
Front Immunol. 2021 May 27;12:688747. doi: 10.3389/fimmu.2021.688747. eCollection 2021.
5
Novel cell and gene therapies for HIV.用于 HIV 的新型细胞和基因疗法。
Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a007179. doi: 10.1101/cshperspect.a007179.
6
CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.HIV 感染者接受 CCR5Δ32 纯合子脐带血异基因移植：病例报告。
Lancet HIV. 2015 Jun;2(6):e236-42. doi: 10.1016/S2352-3018(15)00083-1. Epub 2015 May 19.
7
The use of cell-delivered gene therapy for the treatment of HIV/AIDS.细胞递送基因治疗在 HIV/AIDS 治疗中的应用。
Immunol Res. 2010 Dec;48(1-3):84-98. doi: 10.1007/s12026-010-8169-7.
8
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?HIV-1 感染患者的基因修饰造血干细胞移植：我们能否实现治愈？
Mol Ther. 2014 Feb;22(2):257-264. doi: 10.1038/mt.2013.264. Epub 2013 Nov 13.
9
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.用三重组合抗 HIV 慢病毒载体转导的 CD34(+)造血干细胞生成抗 HIV-1 免疫系统。
J Virol. 2012 May;86(10):5719-29. doi: 10.1128/JVI.06300-11. Epub 2012 Mar 7.
10
From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation.从柏林到伦敦：干细胞移植后 HIV-1 储存库的减少。
Curr HIV/AIDS Rep. 2020 Aug;17(4):385-393. doi: 10.1007/s11904-020-00505-2.
引用本文的文献
1
Clinical hematopoietic stem cell-based gene therapy.基于临床造血干细胞的基因治疗。
Mol Ther. 2025 Jun 4;33(6):2663-2678. doi: 10.1016/j.ymthe.2025.04.029. Epub 2025 Apr 24.
2
Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication.突破治愈HIV-1的障碍：基因编辑、免疫调节和病毒储存库清除方面的创新
Life (Basel). 2025 Feb 11;15(2):276. doi: 10.3390/life15020276.
3
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies.迈向HIV-1缓解：干细胞疗法的见解与创新
Arch Stem Cell Ther. 2024;5(1):5-13. doi: 10.46439/stemcell.5.020.
4
Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects.聚焦病毒感染对造血干细胞（HSCs）的影响，重点探讨 COVID-19 的作用。
Cell Commun Signal. 2023 May 8;21(1):103. doi: 10.1186/s12964-023-01122-3.
5
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin.一种用于递送抗HIV-1 eCD4-Ig孔中旋钮反向免疫粘附素的慢病毒载体B细胞基因治疗平台。
Mol Ther Methods Clin Dev. 2023 Feb 11;28:366-384. doi: 10.1016/j.omtm.2023.02.004. eCollection 2023 Mar 9.
6
Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study.工程化锌指蛋白靶向 2LTR 抑制造血干细胞和祖细胞衍生巨噬细胞中的 HIV 整合：体外研究。
Int J Mol Sci. 2022 Feb 19;23(4):2331. doi: 10.3390/ijms23042331.
7
Stem Cell Therapy and Its Significance in HIV Infection.干细胞疗法及其在HIV感染中的意义。
Cureus. 2021 Aug 27;13(8):e17507. doi: 10.7759/cureus.17507. eCollection 2021 Aug.
8
Research and Clinical Significance of the Differentially Expressed Genes TP63 and LMO4 in Human Immunodeficiency Virus-Related Penile Squamous Cell Carcinoma.TP63 和 LMO4 基因在人类免疫缺陷病毒相关阴茎鳞癌中的差异表达研究及临床意义。
Am J Mens Health. 2021 Mar-Apr;15(2):15579883211011380. doi: 10.1177/15579883211011380.
9
Experimental Treatment of SIV-Infected Macaques via Autograft of -Disrupted Hematopoietic Stem and Progenitor Cells.通过移植经基因编辑的造血干细胞和祖细胞对感染猴免疫缺陷病毒（SIV）的猕猴进行实验性治疗
Mol Ther Methods Clin Dev. 2020 Mar 13;17:520-531. doi: 10.1016/j.omtm.2020.03.004. eCollection 2020 Jun 12.
10
Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells.比较用于清除 HIV 感染细胞的人源单克隆抗体对糖蛋白 41 的各种放射性有效载荷。
Nucl Med Biol. 2020 Mar-Apr;82-83:80-88. doi: 10.1016/j.nucmedbio.2020.02.009. Epub 2020 Feb 19.
本文引用的文献
1
TAL effectors: customizable proteins for DNA targeting.TAL 效应因子：可定制的 DNA 靶向蛋白。
Science. 2011 Sep 30;333(6051):1843-6. doi: 10.1126/science.1204094.
2
Concise review: managing genotoxicity in the therapeutic modification of stem cells.简明综述：干细胞治疗修饰中的遗传毒性管理。
Stem Cells. 2011 Oct;29(10):1479-84. doi: 10.1002/stem.716.
3
On target? Tracing zinc-finger-nuclease specificity.有目标吗？追踪锌指核酸酶的特异性。
Nat Methods. 2011 Aug 30;8(9):725-6. doi: 10.1038/nmeth.1680.
4
Site-specific integration and tailoring of cassette design for sustainable gene transfer.位点特异性整合和盒式设计的定制化用于可持续基因转移。
Nat Methods. 2011 Aug 21;8(10):861-9. doi: 10.1038/nmeth.1674.
5
An unbiased genome-wide analysis of zinc-finger nuclease specificity.锌指核酸酶特异性的无偏基因组分析。
Nat Biotechnol. 2011 Aug 7;29(9):816-23. doi: 10.1038/nbt.1948.
6
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.利用 CXCR4 特异性锌指核酸酶工程化抗 HIV 的人 CD4+ T 细胞。
PLoS Pathog. 2011 Apr;7(4):e1002020. doi: 10.1371/journal.ppat.1002020. Epub 2011 Apr 14.
7
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.尽管病毒复制受到抑制，但 HIV 疾病仍会进展，这与淋巴细胞生成衰竭有关。
Blood. 2011 May 12;117(19):5142-51. doi: 10.1182/blood-2011-01-331306. Epub 2011 Mar 24.
8
Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI.利用工程化归巢内切酶 Y2 I-AniI 成功靶向和破坏整合报告基因慢病毒。
PLoS One. 2011 Feb 9;6(2):e16825. doi: 10.1371/journal.pone.0016825.
9
Long-term regulation of genetically modified primary hematopoietic cells in dogs.长期调控犬体内基因修饰的原代造血细胞。
Mol Ther. 2011 Jul;19(7):1287-94. doi: 10.1038/mt.2011.8. Epub 2011 Feb 15.
10
Clinical use of CCR5 inhibitors in HIV and beyond.CCR5 抑制剂在 HIV 及其他领域的临床应用
J Transl Med. 2011 Jan 27;9 Suppl 1(Suppl 1):S9. doi: 10.1186/1479-5876-9-S1-S9.
Zotero 插件